Related Experiment Video

Updated: Aug 19, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Teniposide (VM-26) in brain tumors

J G McVie1

  • 1Scientific Department, Cancer Research Campaign, London, England.

Seminars in Oncology
|April 1, 1992
PubMed

Insights

Teniposide shows promise for treating brain tumors, particularly small cell lung cancer with brain metastasis, due to preferential uptake in tumor tissue. Further controlled trials are needed to optimize its use in adult glioma treatment.

Area of Science:

  • Neuro-oncology
  • Medical oncology
  • Pharmacology

Background:

  • Teniposide's activity in glioma was noted in 1971.
  • Recent investigations focus on its efficacy in small cell lung cancer and brain metastases.
  • Preferential uptake of teniposide in brain tumor tissue has been observed.

Purpose of the Study:

  • To systematically investigate the effectiveness of teniposide in small cell lung cancer and associated brain metastases.
  • To evaluate the single-agent activity and combination therapy of teniposide in adult glioma.
  • To highlight the need for controlled trials to optimize teniposide's clinical application.

Main Methods:

  • Review of existing literature on teniposide's use in glioma and brain metastases.
  • Analysis of studies reporting single-agent activity in astrocytomas.
  • Examination of combination therapy trials, particularly with nitrosoureas, doxorubicin, and lomustine.

Main Results:

  • Teniposide demonstrates effectiveness in small cell lung cancer and brain metastases.
  • Single-agent activity in astrocytomas is reported, but data interpretation is challenging due to study variations.
  • Combination therapy results are difficult to evaluate consistently due to differing response definitions.

Conclusions:

  • Teniposide shows significant potential for treating adult glioma.
  • Variations in study designs and response definitions hinder definitive evaluation of teniposide's efficacy.
  • Controlled clinical trials are essential to confirm and optimize teniposide's role in glioma treatment.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.